| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T291 |
0-147 |
Sentence |
denotes |
As of now, there is no evidence that naturally developed antibodies toward SARS-CoV-2 contribute to the pathological features observed in COVID-19. |
| T292 |
148-274 |
Sentence |
denotes |
However, this possibility should be considered when it comes to experimental design and development of therapeutic strategies. |
| T293 |
275-409 |
Sentence |
denotes |
Importantly, in all of the descriptions of ADE as it relates to CoV, the FcR was necessary to trigger the antibody-mediated pathology. |
| T294 |
410-669 |
Sentence |
denotes |
High-dose intravenous immunoglobulin (IVIg), which may blunt ADE, has been trialed in COVID-19 patients (Cao et al., 2020b, Shao et al., 2020), but further studies are needed to determine the extent to which IVIg is safe or beneficial in SARS-CoV-2 infection. |
| T295 |
670-927 |
Sentence |
denotes |
Vaccine trials will need to consider the possibility of antibody-driven pathology upon antigen rechallenge; strategies using F(ab) fragments or engineered Fc monoclonal antibodies may prove particularly beneficial in this setting (Amanat and Krammer, 2020). |
